$17,477.54 consulting Payment -- AbbVie Inc to Dr. Amanda Lewis

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This report details a payment of $17,477.54 made by AbbVie Inc. to Dr. Amanda Lewis, a rheumatologist, on September 12, 2025. The payment was for consulting services related to Trulicity, a drug manufactured by AbbVie. Consulting fees are common in the pharmaceutical industry, allowing companies to leverage physician expertise for product development, market research, and educational initiatives. The amount, while substantial, is not necessarily out of the ordinary for specialized consulting roles, especially those involving significant time commitments or unique expertise. Rheumatologists often engage with pharmaceutical companies due to the complex nature of autoimmune and inflammatory diseases, which are frequently treated with specialized, often expensive, medications. Potential conflict of interest is a key consideration. When physicians receive payments from drug manufacturers, it raises questions about whether their prescribing decisions could be influenced by financial ties rather than solely by patient needs and evidence-based medicine. While the Sunshine Act requires disclosure to promote transparency, it doesn't inherently prove bias. Dr. Lewis's consulting role with AbbVie, the maker of Trulicity, means she has a direct financial relationship with a company whose products she might prescribe. This payment is higher than the average payment reported across all physician specialties, but within a range seen for specialized consulting in fields like rheumatology. Patients should understand that such relationships are common but warrant awareness. Transparency allows patients to have informed discussions with their doctors about treatment options and potential influences on care.

Patient Guidance: What This Payment Means for You

It's understandable to feel concerned when you see payments between pharmaceutical companies and your doctor. This payment of $17,477.54 to Dr. Lewis from AbbVie for consulting is a significant amount, indicating a professional relationship beyond routine patient care. While such relationships are legal and often involve sharing valuable expertise, they can create a potential conflict of interest. At your next appointment, consider asking Dr. Lewis directly about her relationship with AbbVie and how it might relate to your treatment. You could ask, 'I saw that you received a consulting payment from AbbVie, the maker of Trulicity. Can you explain how this relationship informs your approach to treating conditions like mine?' It's also helpful to ask about all available treatment options, including generics or alternatives not made by AbbVie, and the reasons behind her specific recommendations. Remember, transparency is key. If you feel uncomfortable or that your concerns aren't being addressed, you have the right to seek a second opinion or discuss your care with another provider.

Payment Context: Is This Amount Normal?

Payments for consulting in rheumatology can vary widely, but $17,477.54 for a single engagement is on the higher end, suggesting a significant role or specialized expertise. While many rheumatologists may receive some form of payment from pharmaceutical companies for activities like speaking or advisory boards, the percentage receiving payments of this magnitude for consulting is likely lower than those receiving smaller honoraria. This payment is considerably higher than the average payment across all physician specialties.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, mandates that pharmaceutical and medical device companies report payments made to physicians and teaching hospitals. This payment, exceeding the $10 threshold, was publicly reported. Consulting fees are a primary category of payments subject to this disclosure. While there's no specific heightened scrutiny for this exact amount, the aggregate data is monitored for patterns that might suggest undue influence on prescribing habits.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• rheumatology
• consulting-fees
• sunshine-act
• conflict-of-interest
• abbvie
• trulicity

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can check if your doctor receives payments from pharmaceutical companies through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Simply search for your doctor's name or National Provider Identifier (NPI). Payments can include consulting fees, speaking fees, meals, travel, and research funding. Seeing a payment doesn't automatically mean your doctor's decisions are compromised, but it does indicate a relationship that warrants awareness and potentially a conversation.

Should I worry about this payment?

This specific payment of $17,477.54 to Dr. Lewis from AbbVie for consulting is substantial. While consulting is a legitimate way for companies to gain physician insights, the amount suggests a significant professional relationship. It's wise to be aware of this financial tie, especially since AbbVie makes Trulicity, a drug she might prescribe. It doesn't automatically mean your care is compromised, but it's a good reason to ensure you're discussing all treatment options openly and understanding the rationale behind her recommendations.

What types of pharma payments are most concerning?

Payments that raise the most concern are often those that are large, frequent, or directly tied to prescribing specific drugs without clear justification. This includes substantial consulting fees, speaking honoraria for promotional events, or significant research grants where the physician's findings might be influenced. While meals and small gifts are also disclosed, they are generally considered less impactful than larger financial arrangements. The key is transparency and ensuring payments don't create an undue influence on clinical judgment.

How do I talk to my doctor about pharma relationships?

Start by acknowledging the transparency provided by the Open Payments database. You could say, 'I noticed you received a payment from [Company Name] for [Payment Type]. Could you help me understand how this relationship works and if it influences your recommendations for my treatment?' Ask about all available treatment options, including generics or alternatives, and the specific reasons for their choice. Frame it as a desire to be an informed patient, not an accusation.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical companies, provided these payments are properly disclosed under the Sunshine Act. The Act requires companies to report payments made to physicians for services like consulting, speaking, research, and more. The goal is transparency, allowing patients and the public to see these financial relationships. However, ethical guidelines still apply, and physicians must ensure their professional judgment remains paramount.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships between doctors and pharmaceutical companies can influence prescribing patterns. Doctors who receive payments may be more likely to prescribe the company's drugs, sometimes even when equally effective, cheaper alternatives exist. However, this influence varies greatly among physicians. Many doctors maintain their professional integrity, but awareness of these potential biases is crucial for patients to ensure they receive the most appropriate and cost-effective care.

How does this compare to other doctors in this specialty?

This $17,477.54 consulting payment to Dr. Lewis is likely higher than the average payment received by rheumatologists overall, as consulting fees tend to be substantial. While many physicians in specialties like rheumatology engage with pharmaceutical companies due to the nature of treatments, the frequency and amount of payments vary. This specific payment suggests a more involved relationship than typical speaker fees or smaller honoraria, placing it above the average for the specialty.

Related Reports

• View Dr. Amanda Lewis's full payment report
• AbbVie Inc full spending report
• Browse all Rheumatology payments
• Browse all payments in New Jersey
• Search for other payments